Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Overweight on Helios Technologies, Lowers Price Target to $71

Keybanc analyst Jeffrey Hammond maintains Helios Technologies (NYSE:HLIO) with a Overweight and lowers the price target from $90 to $71.
byBenzinga Newsdesk
September 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Keybanc analyst Jeffrey Hammond maintains Helios Technologies (NYSE:HLIO) with a Overweight and lowers the price target from $90 to $71.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And ‘Substantial Growth’

By Jelena Martinovic
May 28, 8:42 AM
Canadian cannabis producer and distributor Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) announced on Tuesday its first quarter financial results for the three months ended March 31, 2024. The Toronto-based company reported a total revenue of CA$16.4 million ($12 million) (net revenue of CA$12.7 million, before excise duties and discounts), representing a 9% year-over-year increase. "Entourage's first quarter results are a testament to our robust financial health and strategic approach to business operations, positioning us for success throughout 2024," George Scorsis, the company's chair and CEO, said. "With defined infrastructure and supply agreements in place, we are well-positioned to continue delivering the accelerated growth we have already seen develop in Q1."

ETRGF